UNIVERSITY OF WASHINGTON
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1861-01-01
- Employees
- 10K
- Market Cap
- -
Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer
Phase 2
Terminated
- Conditions
- HER2-positive Breast CancerStage IV Breast CancerMale Breast CancerRecurrent Breast Cancer
- Interventions
- Biological: HER-2/neu peptide vaccine
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2017-04-11
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 3
- Registration Number
- NCT01729884
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients
Not Applicable
Completed
- Conditions
- Anxiety DisorderDuctal Breast Carcinoma in SituPsychosocial Effects of Cancer and Its TreatmentStage IA Breast CancerStage IB Breast CancerStage IIIC Breast CancerDepressionLobular Breast Carcinoma in SituStage IIIB Breast CancerStage II Breast Cancer
- Interventions
- Other: counseling interventionOther: educational interventionOther: psychosocial support for caregiver
- First Posted Date
- 2012-11-08
- Last Posted Date
- 2018-02-08
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 108
- Registration Number
- NCT01723943
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
Not Applicable
Completed
- Conditions
- Male Breast CancerRecurrent Breast CancerStage IV Breast Cancer
- Interventions
- Drug: vorinostatDrug: anastrozoleDrug: letrozoleDrug: exemestaneProcedure: positron emission tomographyRadiation: F-18 16 alpha-fluoroestradiolRadiation: fludeoxyglucose F 18Other: laboratory biomarker analysis
- First Posted Date
- 2012-11-02
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 15
- Registration Number
- NCT01720602
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Pacific Northwest Udall Center (PANUC) Clinical Core
Recruiting
- Conditions
- Parkinson DiseaseCognitive Impairment
- First Posted Date
- 2012-11-02
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 2000
- Registration Number
- NCT01720810
- Locations
- 🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States
Effects of IV Administration of Ketamine on the Analgesia Nociception Index (ANI) Measured With the PhysioDoloris
Completed
- Conditions
- Monitoring, Intraoperative
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2019-08-05
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 20
- Registration Number
- NCT01717521
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
Reducing Disabilities in Alzheimer's Disease (RDAD) Translation in Area Agencies on Aging (AAAs)
Not Applicable
Completed
- Conditions
- Alzheimer's DiseaseDementiaMemory ImpairmentCognitive Impairment
- Interventions
- Behavioral: RDAD
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2017-09-15
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 510
- Registration Number
- NCT01708304
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma
Phase 2
Recruiting
- Conditions
- Recurrent Hodgkin LymphomaRecurrent Non-Hodgkin LymphomaRefractory Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2012-10-11
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 40
- Registration Number
- NCT01703949
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Cabozantinib in Men With Castration-Resistant Prostate Cancer
Phase 2
Terminated
- Conditions
- Castration-resistant Prostate CancerStage III Prostate CancerAdenocarcinoma of the ProstateRecurrent Prostate CancerStage IV Prostate Cancer
- Interventions
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 9
- Registration Number
- NCT01703065
- Locations
- 🇺🇸
Seattle Cancer Care Alliance/University of Washington, Seattle, Washington, United States
Cognitive Behavioral Therapy for COPD
Not Applicable
Completed
- Conditions
- COPDDepression
- Interventions
- Behavioral: CLIMB (COPD Lifestyle, Mood, and Behavior)
- First Posted Date
- 2012-09-27
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 18
- Registration Number
- NCT01694628
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin
Phase 1
Completed
- Conditions
- Insulin ResistanceType 2 Diabetes MellitusObesityAndrogen DeficiencyMetabolic Disease
- Interventions
- Drug: AcylineDrug: Testosterone 1.62% gelDrug: Placebo gel (for Testosterone 1.62% gel)Drug: Placebo pill (for Letrozole)Drug: Letrozole
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2018-05-08
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 53
- Registration Number
- NCT01686828
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
© Copyright 2025. All Rights Reserved by MedPath